Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma US has signed a deal with Tecnofarma International for the distribution of Enzalutamide, referred to as Xtandi in the US, in Latin America, excluding Brazil.
Subscribe to our email newsletter
Following the receipt of regulatory approvals in the various countries in Latin America, Tecnofarma will distribute the US FDA approved product for the treatment of metastatic castration resistant prostate cancer for patients previously treated with docetaxel.
Further financial details of the agreements have not been disclosed.
Astellas Pharma US Latin America vice president Martin Mercer said, "Tecnofarma, with whom Astellas already has a relationship through our Mycamine distribution agreement in Latin America, has a strong Latin American sales and marketing oncology organization, which is why they are an ideal partner to help build the Astellas oncology pipeline with enzalutamide."
Tecnofarma Latin America CEO Jorge Ramos added, "It is an extremely valuable new option for patients in this region."
Xtandi has Health Canada approval for the same indication and pending marketing applications in Japan, Europe, Switzerland, South Korea and Brazil.